Philippines Trial Sites Enrolling Patients for Regulatory Approved Investigation into use of Folk Medicine for COVID-19 Adjunctive Therapy

Philippines Trial Sites Enrolling Patients for Regulatory Approved Investigation into use of Folk Medicine for COVID-19 Adjunctive Therapy

The Philippines national Department of Science and Technology reports that 21 subjects have been enrolled in a clinical trial for an adjunctive therapy targeting COVID-19 involving a medicinal plant known as Lagundi. The trial sites include Quezon Institute Quarantine Center, Sta Ana Hospital and PNP-NCRPO Bagong Diwa Quarantine Center. With 113 patients screened, the study was actually approved by the Philippines Food and Drug Administration (FDA) in August. The ethics of this study was cleared by the University of the Philippines (UP)—Manila Research Ethics Board.

What is Lagundi?

Commonly known as “Chaste tree,” “five-leaved chaste tree,” or “horseshoe vitex” or “nishinda,” this large aromatic shrub is used as a traditional folk medicine in South and Southeast Asia. The Food and Drug Administration of the Philippines has approved for use in COVID-19 clinical trials. TrialSite reported in July that the Philippines Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) approved the clinical trial investigating the use of an herbal medicine called “Lagundi” as a therapeutic supplement for COVID-19. The study was also cleared ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee